• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Establishment of a universal grading system for ovarian epithelial carcinoma

Research Project

Project/Area Number 09671727
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Obstetrics and gynecology
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

SHIMIZU Yoshio  The Cancer Institute, Asociate, 癌研究所, 研究員 (60260072)

Co-Investigator(Kenkyū-buntansha) HASUMI Katsuhiko  The Cancer Institute, Member/Chief, 癌研究所, 部長 (70134608)
AKIYAMA Futoshi  The Cancer Institute, Department of Pathology, Associate member, 癌研究所・病理部, 主任研究員 (50222550)
Project Period (FY) 1997 – 2000
Project Status Completed (Fiscal Year 2000)
Budget Amount *help
¥2,900,000 (Direct Cost: ¥2,900,000)
Fiscal Year 2000: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1999: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1998: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1997: ¥900,000 (Direct Cost: ¥900,000)
Keywordsovarian carcinoma / histopathologic grade / prognosis / 化学療法 / 予後因子 / 組織型 / 分化度 / 悪性度
Research Abstract

The aim of the present study was to establish a universal histopathologic granding system applicable for patients with all histologic types of ovarian epithelial carcinoma(OEC). We first demonstrated that architectural grade(defined by us), nuclear pleomorphism, and mitotic counts were independent and statistically significant prognostic variables for patients with OEC.Then, we awarded points for these three variables, and summed up the scores for a final grade. The scoring system was as follows ; Architectural pattern(predominant) : Glandular=1, Papillary=2, and Solid=3 ; Nuclear pleomorphism : Slight=1, Moderate=2, and Marked =3 ; Mitotic activity(mitotic figures per 10 high-power fields in most active region : 0-9=1, 10-24=2 and 【greater than or equal】 25=3 ; Grade 1=total score 3-5, Grade 2=6 Or 7, and Grade 3=8 or 9. Reproducibility of the scoring was appreciably high (accordance rate : 94%). Subjects included are 538 patients with OEC treated in Cancer Institute Hopspital. 1)The new grade worked as a significant predictor of overall survival in both early and advanced stage disease stratified by FIGO and TNM classification for all histologic types of OEC combined. 2)OEC were classified into distinct two groups, platinum-sensitive(serous, transitional, and endometrioid) and platinum-resistant(mucinous and clear cell). No significant difference in response(CR + PR) to intial platinum-based chemotherapy(CTX) by the new grade. CR rate, however, was significantly lowered in the high-grade disease. Furthermore, progression-free interval, incidence of progression, and the response to the second line CTX was significantly worse in the high-grade (G3)disease. This may indicate that the high-grade disease is more likely to develop acquired resistance These results were reflected in the difference of survival of OEC patients by the new grade. 3)The new grade also worked as a significant prognostic factor for lymph node metastasis.

Report

(5 results)
  • 2000 Annual Research Report   Final Research Report Summary
  • 1999 Annual Research Report
  • 1998 Annual Research Report
  • 1997 Annual Research Report
  • Research Products

    (33 results)

All Other

All Publications (33 results)

  • [Publications] Shimizu Y: "Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma"Jpn J Chem Chemalher. 24. 61-69 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y et al: "Toward the development of a universal grading system for ovarian Epithelial Carcinoma"Cancer. 82. 893-901 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y et al: "Prognostic significance of histopathologic featores"Gopnecol Oncol. 70. 2-12 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y et al.: "Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma"J Clin Oncol. 16. 1869-1878 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] 清水 敬生: "卵巣腫瘍の病理組織学"産科と婦人科. 66. 49-59 (1999)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Y Shimizu et al.: "The Mechanism of cisplatr resistance and its ciraemventior"Yoshihiro Kikuchi. 457 (1998)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y, et al: "Individualized Chemotherapeutic Regimen for Each Histological Subtype of Ovarian Carcinoma"Jpn J Cancer Chemother. 24 : Supplment l. 61-69 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y, et al: "Cytotoxic agents active against mucinous adenocarcinoma of the ovary"Oncol Reports. 5. 99-101 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y, et al: "Toward the development of a universal grading system for ovarian epithelial carcinoma. Testing of a proposed system in a series of 461 patients with uniform treatment and follow-up"Cancer. 82. 893-901 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y, et al: "Toward the development of a universal grading system for ovarian epithelial carcinoma. I.Prognostic significance of histopathologic features-----Problems involved in the architectural grading system"Gynecol Oncol. 70. 2-12 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] Shimizu Y, et al: "Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma"J Clin Oncol. 16. 1869-1878 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2000 Final Research Report Summary
  • [Publications] 清水敬生: "卵巣癌の化学療法"産婦治療. 80. 169-173 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 清水敬生: "卵巣癌の化学療法up-date"産科と婦人科. 67. 712-723 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 清水敬生: "卵巣癌:DDP dose intensityの観点から"key trial がん. 2. 18-22 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] Shimigu Y et al: "Effect of human urinary MCSF on the immune and the blood cell counts in patients and ovarian cancer"

    • Related Report
      2000 Annual Research Report
  • [Publications] 清水敬生: "インフォームド・コンセントガイダンス婦人科治療編"野田起一郎. 341 (2000)

    • Related Report
      2000 Annual Research Report
  • [Publications] 清水敬生: "卵巣癌化学療法の効果増強のための工夫"日産婦誌. 51. 562-574 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 清水敬生: "卵巣腫瘍の病理組織学"産科と婦人科. 66. 49-59 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 清水敬生: "子宮体部明細胞腺癌"産科と婦人科. 66. 135-140 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 清水敬生: "高齢者の癌治療・・・・卵巣癌を対象として"Practical Oncology. 12. 12-14 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 清水敬生: "再発卵巣癌の治療"産婦人科治療. 78. 133-139 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] 清水敬生: "卵巣癌neoadjuvant化学療法"婦人科がん化学療法 クリンカルブラクティス. 66. 125-130 (1999)

    • Related Report
      1999 Annual Research Report
  • [Publications] Y.Shimizu et al: "Toward the development of a universal grading system for ovarian epithelial carcinoma" Cancer. 82. 893-901 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Y.Shimizu et al: "Progrrostic signification of historatholigic features" Gynecologic Oncology. 70. 2-12 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Y.Shimizu et al: "Combination of conselecture low-dose cisplatin wab fleomycin, vincristine,and mitomysin for recurrent cervical cancer" J.Clin.Oncology. 16. 1869-1878 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Y.SHIMIZU et al: "A Phase II study of Combined CPT-11 and Mitomysin C in Platinum refractoy clear cell and mucinoma ovrian carcinoma" Han Acid Med Singapore. 16. 1869-1878 (1998)

    • Related Report
      1998 Annual Research Report
  • [Publications] Shimizu Y.: "Pharmaco Kinetics of consecutive low-close cisplatin." Oncology Reports. 4. 591-593 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Shimizu Y: "Individnalized chems the rapoutis regimen for end tristologicel cubtype of ovarian carcinoma." Jpn J Cancer Ehlxiother. 24. 61-69 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Shimizu Y et al: "Activity of cytotoxic agents against clear coll carcinoma of the ovary which is in rincicelly platinum-refrectvy" Oncology Reports. 4. 945-948 (1997)

    • Related Report
      1997 Annual Research Report
  • [Publications] Shimizu Y et al: "Cysotoxic agents active against mucinons adluo careinom of the ovary" Oncol Reports. 5. 99-101 (1998)

    • Related Report
      1997 Annual Research Report
  • [Publications] Shimizu Y et al: "Toward the development of a universal grading system for ovarian cancer" Cancer. 82. 893-901 (1998)

    • Related Report
      1997 Annual Research Report
  • [Publications] Shimizu Y.et al: "Combinetion of consecutive low-close cisplatin with fleomy an,vincuistine,and mioomycin for recensent cervicel cauinoma." J.Clmi Onol. 16. (1998)

    • Related Report
      1997 Annual Research Report
  • [Publications] Y.Shimizu et al: "The mechenism of cisplatin resistance and its circumvention" Yoshihiro Kikuchi, 457 (1998)

    • Related Report
      1997 Annual Research Report

URL: 

Published: 1997-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi